Previsioni

Il prezzo obiettivo medio degli analisti è +32,60€ (+80,61%). La mediana è +32,60€ (+80,61%).

Acquista	5
Mantieni	4
Vendi	1

Notizie Vai al feed delle notizie

Innoviva: three therapies named finalists for Prix Galien USA 2026

Innoviva Specialty Therapeutics has confirmed three products — XACDURO, ZEVTERA and NUZOLVENCE — as finalists for the Prix Galien USA Award 2026 in the category “best pharmaceutical product.” XACDURO is approved for hospital- and ventilator-associated bacterial pneumonia caused by Acinetobacter, ZEVTERA is a cephalosporin approved in 2024 for Staphylococcus aureus, and NUZOLVENCE is a 2025-approved oral single-dose therapy for resistant gonorrhea. This is the third consecutive recognition of an Innoviva product by the Galien Foundation; the winners will be announced on October 29, 2026. » Altro su de.investing.com
Innoviva launches Nortiva Bio to develop long-acting oral LYNX platform

Innoviva launched Nortiva Bio, a wholly owned subsidiary to advance the LYNX long-acting oral drug delivery platform that can convert daily medicines into extended-release therapies with potential dosing up to one month. The move follows Innoviva’s 2025 acquisition of the LYNX platform from Lyndra Therapeutics. Separately, Innoviva Specialty Therapeutics signed an exclusive distribution and licensing deal with Dr. Reddy's for XACDURO in parts of Latin America, the Caribbean, Russia and CIS, with upfront, milestone and royalty payments outlined. » Altro su finance.yahoo.com
Innoviva reaches 52-week high, analysts see further upside

Innoviva's stock rose to a 52-week high of $24.02; the company has a market capitalization of about $1.79 billion and a price-to-earnings ratio of 15.69. Analysts and InvestingPro fair-value estimates continue to view the stock as undervalued with upside potential; BTIG initiated coverage with a "Buy" and a $35 price target and expects roughly $1.2 billion in licensing revenue from two inhalation therapies by 2030. In addition, Innoviva Specialty Therapeutics received FDA approval for NUZOLVENCE, a single-dose oral treatment for uncomplicated urogenital gonorrhea, strengthening the strategic growth outlook. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2015, Innoviva ha già distribuito 0,67€ di dividendi. L'ultimo pagamento è avvenuto a settembre 2015.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Innoviva ha registrato ricavi pari a 104.79m€ e un utile netto di −73.09m€

(EUR)	giu 2026	YoY
Ricavi	+104.79m	23,16%
Utile lordo	+79.40m	4,34%
Utile netto	−73.09m	235,27%
EBITDA	+234.14m	229,29%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+1.33b€
Numero di azioni	73.81m
Massimo/minimo a 52 settimane	+21,58€ - +14,17€
Dividendi	No
Beta	0,34
Rapporto P/E	+4,32
Rapporto PEG	+0,01
Rapporto P/B	+1,25
Rapporto P/S	+3,50

Profilo aziendale

Innoviva, Inc. beschäftigt sich mit der Entwicklung und Vermarktung von Arzneimitteln in den Vereinigten Staaten und international. Zu seinen Produkten gehören RELVAR/BREO ELLIPTA, ein einmal täglich zu verabreichendes Kombinationspräparat aus einem LABA, Vilanterol (VI), einem inhalativen Kortikosteroid (ICS) und Fluticasonfuroat; ANORO ELLIPTA, ein einmal täglich zu verabreichendes Medikament, das einen lang wirkenden Muskarin-Antagonisten (LAMA), Umeclidiniumbromid (UMEC), mit einem LABA und VI kombiniert; und TRELEGY ELLIPTA, ein einmal täglich zu verabreichendes Kombinationsmedikament, das aus einem ICS, LAMA und LABA besteht. Innoviva, Inc. hat eine strategische Partnerschaft mit Sarissa Capital Management LP. Das Unternehmen hat eine Kooperationsvereinbarung mit der Glaxo Group Limited über langwirksame Beta2-Agonisten (LABA) zur Entwicklung und Vermarktung von einmal täglich einzunehmenden Produkten für die Behandlung von chronisch-obstruktiven Lungenerkrankungen und Asthma. Das Unternehmen war früher als Theravance, Inc. bekannt und änderte im Januar 2016 seinen Namen in Innoviva, Inc. Innoviva, Inc. wurde 1996 gegründet und hat seinen Hauptsitz in Burlingame, Kalifornien.

Nome	Innoviva
CEO	Pavel Raifeld
Sede centrale	Burlingame, ca Stati Uniti
Sito web	inva.com
Settore	Materiali
Industria	Prodotti chimici
Quotazione in borsa	05/10/2004
Dipendenti	159